| 05/12 | HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy R.. | MT |
| 05/11 | Pfizer's $11.6 billion Biohaven buy could spark more biotech deals | RE |
| 05/05 | Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81.. | MT |
| 05/05 | VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 05/05 | Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $1.23B, vs. Street Est of $81.. | MT |
| 05/05 | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re.. | GL |
| 05/05 | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Re.. | AQ |
| 05/05 | Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, .. | CI |
| 05/02 | INSIDER SELL : Vir Biotechnology | MT |
| 04/27 | TRANSCRIPT : Vir Biotechnology, Inc. - Special Call | CI |
| 04/27 | Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa.. | GL |
| 04/27 | Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepa.. | GL |
| 04/27 | GSK tops forecasts as consumer health spin-off nears | RE |
| 04/23 | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vir B.. | PR |
| 04/21 | Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial R.. | GL |
| 04/13 | Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day | AQ |
| 04/11 | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors Vir Biot.. | PR |
| 04/08 | Vir Biotechnology Appoints Johanna Friedl-Naderer as COO | MT |
| 04/07 | VIR BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers, Financial Statements .. | AQ |
| 04/07 | Vir Biotechnology, Inc. Appoints Johanna Friedl-Naderer as Executive Vice President and.. | CI |
| 04/06 | Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COV.. | GL |
| 04/05 | Vir Biotechnology Says FDA Exclusion Applied to Sotrovimab in March Now Extended to 'Al.. | MT |
| 04/05 | VIR BIOTECHNOLOGY, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 04/05 | Vir Biotechnology, Inc. Announces FDA's Exclusion Has Been Extended to All U.S. Regions | CI |
| 04/05 | FDA pulls authorization for GSK-Vir's COVID therapy as BA.2 cases rise | RE |
| 04/04 | Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference | AQ |
| 04/04 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500 | CI |
| 04/04 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 | CI |
| 04/04 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care | CI |
| 04/04 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 1000 | CI |
| 04/01 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500 | CI |
| 04/01 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 | CI |
| 04/01 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care | CI |
| 03/31 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 | CI |
| 03/31 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500 | CI |
| 03/31 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care | CI |
| 03/30 | SECTOR UPDATE : Health Care Stocks Close Slightly Lower | MT |
| 03/30 | SECTOR UPDATE : Health Care Stocks Still Trying to Find Direction | MT |
| 03/30 | Top Midday Gainers | MT |
| 03/30 | Vir Biotechnology Shares Rise Amid Joining S&P SmallCap 600 Next Month | MT |
| 03/30 | WALL STREET STOCK EXCHANGE : Should you buy on the cannons? | |
| 03/30 | HC Wainwright Adjusts Vir Biotechnology's Price Target to $200 From $300, Reiterates Bu.. | MT |
| 03/30 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 | CI |
| 03/30 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care | CI |
| 03/30 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500 | CI |
| 03/29 | Camden Property to Join S&P 500; Matador to Join MidCap 400; Vir Biotech to Join SmallC.. | MT |
| 03/29 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 | CI |
| 03/29 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P 600 Health Care | CI |
| 03/29 | VIR BIOTECHNOLOGY, INC.(NASDAQGS : VIR) added to S&P Composite 1500 | CI |
| 03/28 | Needham Adjusts Vir Biotechnology's Price Target to $45 from $80, Keeps Buy Rating | MT |
| 03/27 | US FDA Limits Use of GSK's COVID-19 Antibody to Certain Regions Amid Omicron Subvariant | MT |
| 03/25 | ADRs End Mostly Lower; NIO Traded Actively | DJ |
| 03/25 | VIR BIOTECHNOLOGY : US Food and Drug Administration Revises Emergency Use Authorization fo.. | PU |
| 03/25 | FDA says current dose of GSK-Vir COVID therapy unlikely to work against BA.2 variant | RE |
| 03/25 | FDA Limits Use of Sotrovimab to Treat Covid-19 Due to BA.2 Omicron Subordinated-variant | DJ |
| 03/25 | FDA Rules Smaller Doses of Vir, GlaxoSmithKline Monoclonical Antibody 'Unlikely' to be .. | MT |
| 03/25 | VIR BIOTECHNOLOGY, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 03/25 | US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due .. | GL |
| 03/25 | US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due .. | GL |
| 03/24 | EU medicines regulator recommends AstraZeneca's drug for COVID prevention | RE |
| 03/11 | COVID SCIENCE-GeoVax vaccine targeting virus in two places shows promise; virus may bec.. | RE |
| 03/04 | NORTH AMERICAN MORNING BRIEFING : Stock Futures -2- | DJ |
| 03/03 | Baird Upgrades Vir Biotechnology to Neutral From Underperform, Adjusts Price Target to .. | MT |
| 03/02 | WHO recommends Merck's COVID pill for high-risk patients | RE |
| 03/02 | Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference | AQ |
| 02/28 | VIR BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition an.. | AQ |
| 02/25 | Vir Biotechnology Swings to Q4 Earnings as Revenue Climbs | MT |
| 02/24 | VIR BIOTECHNOLOGY : Provides Corporate Update and Reports Fourth Quarter and Full Year 202.. | PU |
| 02/24 | VIR BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Regulation FD Dis.. | AQ |
| 02/24 | Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year E.. | CI |
| 02/24 | Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $812.7M, vs. Street Est of $6.. | MT |
| 02/24 | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 20.. | AQ |
| 02/24 | US FDA Restricts Use of GlaxoSmithKline-Vir Biotechnology's COVID-19 Shot in Some Regio.. | MT |
| 02/24 | GlaxoSmithKline's Covid-19 Treatment Use Limited by FDA | DJ |
| 02/23 | U.S. FDA limits use of GlaxoSmithKline-Vir COVID-19 drug | RE |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
